San Diego-based molecular diagnostic company, DermTech, Inc., has emerged as a key player in the non-invasive genomics testing sector, offering a range of innovative tests aimed at improving diagnosis and management of skin cancer and inflammatory diseases in the United States. Among its offerings are the DermTech Melanoma Test, which provides a breakthrough, non-invasive way to enhance melanoma detection, as well as the DermTech Smart Sticker, allowing for the collection of skin samples without the need for invasive biopsies. The company also provides research services and technology platform on a contract basis to pharmaceutical companies, which use the technology for clinical trials, and develops gene expression assays for Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. These assays are sold to pharmaceutical companies as part of their drug development efforts in the quickly-growing dermatology industry. DermTech's products are available through pathology and oncology practitioners, making it an increasingly important company in the field of diagnostic medicine.
DermTech's ticker is DMTK
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at DermTech
It is dermtech.com
DermTech is in the Healthcare sector
DermTech is in the Diagnostic Substances industry
The following five companies are DermTech's industry peers: